Voyager Therapeutics, Inc. develops genetic medicines and other neurotherapeutics for neurological diseases, with company updates focused on its CNS pipeline and delivery platforms. Recurring news covers the TRACER AAV capsid discovery platform, intravenous gene-therapy research, Voyager NeuroShuttle nonviral delivery work, and programs addressing Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, ALS, frontotemporal dementia and other central nervous system disorders.
Company announcements also cover tau-focused assets such as VY1706 and VY7523, small-molecule discovery collaboration targeting TDP-43 pathology, scientific conference presentations, and periodic financial and operating results. Voyager’s updates frequently connect pipeline spending, collaboration revenue, partner programs and balance-sheet resources with its genetic-medicine development strategy.
Voyager Therapeutics (Nasdaq: VYGR) reported a narrower third-quarter net loss of $24.7 million as operating expenses declined year over year. Collaboration revenue fell to $4.0 million from $13.4 million, while net loss per share narrowed to $0.40 from $0.47. Cash, cash equivalents and marketable securities totaled $132.1 million at September 30, 2026.
Voyager expects funding into Q2 2028 under current operating plans, including anticipated collaboration reimbursements and interest income. VY7523 Alzheimer’s disease imaging data remain expected in Q4 2026 after completion of the last patient visit. VY1706 dosing is expected in the next few months, pending enrollment, with initial acute safety data expected in Q1 2027. Partner Neurocrine expects the Friedreich’s ataxia gene therapy program NBIB-‘223 to enter Phase 1 in the coming months, with initial patient-level data anticipated in 2027.
Voyager Therapeutics (VYGR) announced two poster presentations for the CTAD conference in Boston, taking place November 16–19, 2026. The posters cover the first-in-human study design of VY1706, an investigational tau-lowering gene therapy, and baseline characteristics of participants in a multiple ascending dose study of VY7523, an anti-tau antibody. Both focus on early Alzheimer’s disease and will be presented November 16–17, 2026.
Voyager Therapeutics (VYGR) appointed Robin Swartz president effective October 20, 2026, as part of a planned CEO succession. Swartz, previously chief business officer and chief operating officer, is expected to succeed Alfred W. Sandrock Jr. as CEO in Q1 2027, following receipt of initial acute safety data from the VY1706 clinical trial.
VY1706 is an investigational gene therapy designed to silence tau in adults with early Alzheimer’s disease. Voyager expects the initial acute safety data in Q1 2027, pending enrollment. Sandrock is expected to remain CEO through that milestone and subsequently continue on the board. Swartz joined Voyager in 2021 and has led functions including clinical development and finance. Before Voyager, she spent 26 years at Genzyme and Sanofi Genzyme.
Voyager Therapeutics (Nasdaq: VYGR) will participate in several September 2026 investor conferences, including events hosted by Wells Fargo, Cantor, Morgan Stanley, Baird, and H.C. Wainwright. Each conference will feature a fireside chat, with the Wells Fargo session webcast live and archived for at least 30 days on Voyager’s investor website.
Voyager Therapeutics (Nasdaq: VYGR) reported second quarter 2026 results, highlighting progress in its Alzheimer’s pipeline and a strengthened cost profile. Tau-targeted antibody VY7523 is expected to deliver tau PET imaging efficacy data in Q4 2026, while tau-silencing gene therapy VY1706 received FDA IND clearance and a Health Canada CTA, with first dosing in early Alzheimer’s patients planned for Q4 2026.
Collaboration revenue was $3.2 million, down from $5.2 million a year earlier. R&D expenses fell to $22.0 million from $31.3 million, and G&A to $7.5 million from $10.5 million, narrowing net loss to $24.5 million from $33.4 million. Voyager ended the quarter with $148.8 million in cash, cash equivalents and marketable securities and expects its cash resources and anticipated collaboration reimbursements to fund operations into 2028.
Voyager Therapeutics (Nasdaq: VYGR) reported six-month GLP toxicology results for VY1706, its investigational tau-targeted gene therapy for Alzheimer’s disease, presented as a Developing Topics poster at AAIC 2026 in London. A single intravenous dose in non-human primates was well tolerated and produced sustained reductions of up to 75% in MAPT mRNA and tau protein in key Alzheimer’s-relevant brain regions over six months.
According to Voyager, VY1706 showed no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, or peripheral organs, including liver, up to the highest dose tested of 5E13 vg/kg. The company received FDA IND clearance for VY1706 in June, enabling initiation of a clinical trial in adults with early Alzheimer’s disease, with dosing expected to start in the second half of 2026. Voyager also reports that ALPL-mediated blood-brain barrier transport supports potential cross-species translatability.
Voyager Therapeutics (Nasdaq: VYGR) will present a Developing Topics poster on its investigational gene therapy VY1706 for Alzheimer’s disease at AAIC 2026 in London, July 12–15, 2026.
VY1706 recently received FDA IND clearance, enabling a clinical trial in adults with early Alzheimer’s, with dosing expected in the second half of 2026.
Voyager Therapeutics (Nasdaq: VYGR) announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.
The on-demand webcast will be available via the Investors section of Voyager’s website starting 7:00 a.m. ET on June 15, 2026, and will be archived for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR) received FDA IND clearance for VY1706, an IV-delivered gene therapy designed to reduce intracellular and extracellular tau in the brain for early Alzheimer’s disease.
The multi-site, open-label, dose-escalation trial will enroll up to 18 adults, with dosing expected in H2 2026.
Voyager Therapeutics (Nasdaq: VYGR) reported 3-month GLP toxicology data for VY1706, an investigational tau-silencing gene therapy for Alzheimer’s disease. A single IV dose was well tolerated in non-human primates up to 5E13 vg/kg and lowered tau protein up to 64% in key brain regions.
The IND process for VY1706 is on track for Q2 2026, supporting expected first-in-human dosing in H2 2026. Additional ASGCT presentations highlighted TRACER-powered AAV capsids with up to 100X higher muscle expression than AAV9 in mice, antibody-evasive “stealth” capsids, and manufacturing optimizations.